Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 18/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21906148 | 0.87 | SCN10A (0.47) | SCN10AADRB2MBOAT4 | |
| SCHEMBL23779599 | 0.85 | ALDH1A1 (0.42) | SCN10A | |
| SCHEMBL30562769 | 0.84 | SCN10A (0.38) | SCN10AADRB2MBOAT4 | |
| SCHEMBL25387182 | 0.84 | SCN10A (0.38) | SCN10AADRB2MBOAT4 | |
| SCHEMBL26608272 | 0.84 | SCN10A (0.51) | SCN10AADRB2 | |
| SCHEMBL30593108 | 0.82 | SCN10A (0.41) | SCN10AADRB2MBOAT4 | |
| SCHEMBL26608619 | 0.82 | SCN10A (0.41) | SCN10AADRB2MBOAT4 | |
| SCHEMBL21906142 | 0.82 | SCN10A (0.54) | SCN10A | |
| SCHEMBL25388582 | 0.81 | SCN10A (0.60) | SCN10A | |
| SCHEMBL30562780 | 0.81 | SCN10A (0.60) | SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250154109-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC | 2025-05-15 | — | — | US | disclosed |
| CN-119677737-A | Heteroaryl compounds for the treatment of pain | 沃泰克斯药物股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250084064-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-03-13 | — | — | US | disclosed |
| CN-119546580-A | Heteroaryl compounds for the treatment of pain | 沃泰克斯药物股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4511115-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-4511116-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2025029890-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-12195445-B2 | 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2023205463-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205468-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023150201-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150201-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20220289710-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-09-15 | — | — | US | disclosed |
| US-11377438-B2 | 2-amino-n-heteroaryl-nicotinamides as Nav1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210387966-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-16 | — | — | US | disclosed |
| EP-3873893-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-113272293-A | 2-amino-N-heteroaryl-nicotinamide as NAV1.8 inhibitors | 默沙东公司 | 2021-08-17 | — | — | CN | disclosed |
| US-20200140411-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154109-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | SCN8A, TRPV1, SCNN1A | SCN10A 7/4885ADRB2 540/4885MBOAT4 3783/4885 |
| US-12195445-B2 | 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors | SCN8A, SCN2A, SCN1A | SCN10A 10/4885ADRB2 478/4885MBOAT4 4725/4885 |
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN8A, SCN1B, SCN3A | SCN10A 22/4885ADRB2 154/4885MBOAT4 3142/4885 |
| US-20250084064-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | SCN10A 10/4885ADRB2 478/4885MBOAT4 4725/4885 |
| US-11377438-B2 | 2-amino-n-heteroaryl-nicotinamides as Nav1.8 inhibitors | SCN8A, SCN2A, SCN1A | SCN10A 10/4885ADRB2 478/4885MBOAT4 4725/4885 |
| US-20220289710-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | SCN10A 10/4885ADRB2 478/4885MBOAT4 4725/4885 |
| US-20210387966-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | SCN10A 10/4885ADRB2 478/4885MBOAT4 4725/4885 |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | TRPV1, SCN3A, KCNN3 | SCN10A 10/4885ADRB2 246/4885MBOAT4 2657/4885 |
| US-20200140411-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | SCN10A 10/4885ADRB2 478/4885MBOAT4 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.